Earnings Are Growing at YiChang HEC ChangJiang Pharmaceutical (HKG:1558) but Shareholders Still Don't Like Its Prospects
Earnings Are Growing at YiChang HEC ChangJiang Pharmaceutical (HKG:1558) but Shareholders Still Don't Like Its Prospects
Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame long term YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) shareholders for doubting their decision to hold, with the stock down 48% over a half decade. Even worse, it's down 12% in about a month, which isn't fun at all.
理想情况下,您的整体投资组合应超过市场平均水平。但是,几乎每个投资者都肯定会有表现过硬和表现不佳的股票。因此,我们不会指责宜昌东芝长江药业有限公司(HKG: 1558)的长期股东怀疑他们的持股决定,该股在五年内下跌了48%。更糟糕的是,它在大约一个月内下降了12%,这一点都不好玩。
Since YiChang HEC ChangJiang Pharmaceutical has shed HK$431m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.
由于宜昌HEC长江药业在过去7天内已从其市值下跌了4.31亿港元,让我们看看长期下跌是否是由该业务的经济推动的。
See our latest analysis for YiChang HEC ChangJiang Pharmaceutical
查看我们对宜昌HEC长江药业的最新分析
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
在他的文章中 格雷厄姆和多兹维尔的超级投资者 沃伦·巴菲特描述了股价如何并不总是合理地反映企业的价值。通过比较每股收益(EPS)和一段时间内的股价变化,我们可以了解投资者对公司的态度是如何随着时间的推移而变化的。
YiChang HEC ChangJiang Pharmaceutical became profitable within the last five years. That would generally be considered a positive, so we are surprised to see the share price is down. Other metrics might give us a better handle on how its value is changing over time.
宜昌东芝长江药业在过去五年内实现盈利。这通常会被视为利好,因此我们惊讶地看到股价下跌。其他指标可能会让我们更好地了解其价值如何随着时间的推移而变化。
It could be that the revenue decline of 3.2% per year is viewed as evidence that YiChang HEC ChangJiang Pharmaceutical is shrinking. This has probably encouraged some shareholders to sell down the stock.
每年3.2%的收入下降可能被视为宜昌HEC长江药业萎缩的证据。这可能鼓励了一些股东抛售该股。
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
您可以在下面看到收入和收入如何随着时间的推移而变化(点击图片了解确切的值)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240129/0-e5c4f7f00dc4dff625c363344503559f-0-671a38644ab6a81736c077b8a6262516.png/big)
We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. So it makes a lot of sense to check out what analysts think YiChang HEC ChangJiang Pharmaceutical will earn in the future (free profit forecasts).
我们很高兴地向大家报告,首席执行官的薪酬比资本相似公司的大多数首席执行官要低得多。始终值得关注首席执行官的薪酬,但更重要的问题是公司多年来是否会增加收益。因此,看看分析师认为宜昌HEC长江药业未来的收入(自由利润预测)是很有意义的。
What About The Total Shareholder Return (TSR)?
那么股东总回报(TSR)呢?
We've already covered YiChang HEC ChangJiang Pharmaceutical's share price action, but we should also mention its total shareholder return (TSR). Arguably the TSR is a more complete return calculation because it accounts for the value of dividends (as if they were reinvested), along with the hypothetical value of any discounted capital that have been offered to shareholders. YiChang HEC ChangJiang Pharmaceutical's TSR of was a loss of 45% for the 5 years. That wasn't as bad as its share price return, because it has paid dividends.
我们已经报道了宜昌东芝长江药业的股价走势,但我们也应该提及其股东总回报率(TSR)。可以说,股东总回报率是一种更完整的回报计算方法,因为它考虑了股息的价值(就好像是再投资一样),以及向股东提供的任何贴现资本的假设价值。宜昌东芝长江药业的股东回报率在5年内亏损了45%。这还不如其股价回报率那么糟糕,因为它已经支付了股息。
A Different Perspective
不同的视角
We're pleased to report that YiChang HEC ChangJiang Pharmaceutical shareholders have received a total shareholder return of 14% over one year. There's no doubt those recent returns are much better than the TSR loss of 8% per year over five years. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. Before forming an opinion on YiChang HEC ChangJiang Pharmaceutical you might want to consider these 3 valuation metrics.
我们很高兴地报告,宜昌东营长江药业的股东在一年内获得了14%的总股东回报率。毫无疑问,最近的回报远好于五年内每年8%的股东总回报率亏损。长期亏损使我们保持谨慎,但短期股东总回报率的增长无疑暗示着更光明的未来。在对宜昌HEC长江药业形成意见之前,你可能需要考虑这三个估值指标。
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
如果你像我一样,那么你不会想错过这份业内人士正在收购的成长型公司的免费名单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.
请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。